Serotonin and interactions

DXM FAQ 1997: selective audit by topic

Serotonin toxicity, MAO inhibitors, antidepressants and diphenhydramine.

Serotonin toxicity: clinical cases

Serotonin toxicity involving DXM is described in clinical publications. It should be presented as a documented complication, particularly in combinations with serotonergic agents.

Corrected

According to the 2026 audit · edition

Evidence and limitations

What was examined: Monte reviews overdose cases involving products with DXM and chlorpheniramine. Harada describes a fatal case involving overdose of DXM and moclobemide. The Auvelity label also carries a warning.

Limits of the conclusion: Clinical cases establish that the complication can occur; its frequency across all doses and combinations is difficult to determine from them.

Sources: Monte — serotonin toxicity Harada — DXM and moclobemide Auvelity — current label

Historical paraphrase · FAQ 4.0 · 1997 · §6.2.9 The FAQ places serotonin syndrome under a theoretical heading, although its text already discusses hazardous combinations.

This claim in the 2026 audit · Erowid archive (HTML 4.0-Y.1) · §6.2.9 · Serotonin Syndrome

The warning about MAO inhibitors

The warning remains applicable and deserves prominent presentation. Modern clinical reports and prescription labeling add to the historical basis.

Retained

According to the 2026 audit · edition

Evidence and limitations

What was examined: Harada describes a fatal case involving moclobemide. The Auvelity label contraindicates combination with MAO inhibitors and includes specific provisions for linezolid and intravenous methylene blue.

Limits of the conclusion: Specific medicine restrictions are checked against the current label for the product concerned. This section examines the historical text.

Sources: William White — historical DXM FAQ Harada — DXM and moclobemide Auvelity — current label

Historical paraphrase · FAQ 4.0 · 1997 · §6.2.9 White already warned of a potentially fatal combination of DXM with MAO inhibitors.

This claim in the 2026 audit · Erowid archive (HTML 4.0-Y.1) · §6.2.9 · Serotonin Syndrome

Antidepressants: two interaction pathways

It is important to distinguish changes in DXM exposure from the combination’s serotonergic effects. Both pathways matter for fluoxetine and paroxetine.

Clarified

According to the 2026 audit · edition

Evidence and limitations

What was examined: Chyka’s clinical guideline accounts for interacting medicines; the Auvelity label includes a serotonin-syndrome warning and information about CYP2D6 inhibition.

Limits of the conclusion: The pathways can coexist. Their contribution depends on the particular medicine, regimen and other ingredients.

Sources: Monte — serotonin toxicity Chyka — clinical poisoning guideline Auvelity — current label

Historical paraphrase · FAQ 4.0 · 1997 · §9.5.1 The FAQ describes CYP2D6 inhibition by fluoxetine.

This claim in the 2026 audit · Erowid archive (HTML 4.0-Y.1) · §9.5.1 · Factors Affecting Metabolism of DXM

Diphenhydramine: an overly broad safety judgment

That broad judgment should be removed. Diphenhydramine’s own sedative and antimuscarinic effects matter, as does its inhibition of CYP2D6.

Corrected

According to the 2026 audit · edition

Evidence and limitations

What was examined: Hamelin demonstrated effects of diphenhydramine on CYP2D6-dependent metoprolol metabolism in humans. Chyka’s guideline calls for considering accompanying ingredients in DXM poisoning.

Limits of the conclusion: Hamelin’s study used metoprolol. Quantifying the interaction directly with DXM requires its own data.

Sources: Hamelin — diphenhydramine and CYP2D6 Chyka — clinical poisoning guideline

Historical paraphrase · FAQ 4.0 · 1997 · §6.1.3 The FAQ describes the combination with diphenhydramine as probably safe.

This claim in the 2026 audit · Erowid archive (HTML 4.0-Y.1) · §6.1.3 · Mild Allergic Reactions and Histamine Release

Sources for this topic
  1. William White — historical DXM FAQ — Historical archive

    The edition label and date of text version 4.0 and the Erowid HTML archive label (4.0-Y.1) were checked. The archive contains later edits.

  2. Monte — serotonin toxicity — PubMed abstract
  3. Harada — DXM and moclobemide — PubMed abstract
  4. Hamelin — diphenhydramine and CYP2D6 — PubMed abstract
  5. Chyka — clinical poisoning guideline — PubMed abstract
  6. Auvelity — current label — Official label

    Indications, ingredients, interactions and mechanism were checked in the label revised in August 2026.

All update topics · Review coverage

Reference

Open the source and related combinations →